http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016130451-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7295065222c58034d229e83c88ccc46 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-31 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 |
| filingDate | 2016-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2f66fdc4d8b278a092a54bab92ca7b1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e7f1e94b92a5e1dfe649159d6097a6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_988af315915dae67798c84091bdd1a73 |
| publicationDate | 2016-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2016130451-A1 |
| titleOfInvention | Increasing the half-life of a full-length or a functional fragment of variant anti-human tnf-alpha antibody |
| abstract | Tumor Necrosis Factor-α (TNFα) promotes an inflammatory response resulting in many clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa, and refractory asthma. Dysregulation of TNF production is implicated in a variety of human diseases including Alzheimer's disease, cancer, major depression, and inflammatory bowel disease. These disorders are treated with a TNFα inhibitor. Embodiments herein provide methods of preventing and/or treating acute and chronic inflammation, and autoimmune diseases by administering a prophylactic and/or therapeutic formulation containing an antibody fragment (Fab or F(ab') 2 ) of adalimumab modified by conjugation of natural amino acids such as proline, alanine and/or serine (PA/S) by PASylation ® , and/or unnatural amino acids such as cysteine and other derivatives, thereby creating a polypeptide possessing none of the processing, preparation, formulation, cost, clinical performance, and other long-term issues of administering PEGylated drugs. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022087149-A2 |
| priorityDate | 2015-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 190.